These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 30302011)

  • 1. Structural Rearrangements Maintain the Glycan Shield of an HIV-1 Envelope Trimer After the Loss of a Glycan.
    Ferreira RC; Grant OC; Moyo T; Dorfman JR; Woods RJ; Travers SA; Wood NT
    Sci Rep; 2018 Oct; 8(1):15031. PubMed ID: 30302011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in Structure and Antigenicity of HIV-1 Env Trimers Resulting from Removal of a Conserved CD4 Binding Site-Proximal Glycan.
    Liang Y; Guttman M; Williams JA; Verkerke H; Alvarado D; Hu SL; Lee KK
    J Virol; 2016 Oct; 90(20):9224-36. PubMed ID: 27489265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natively glycosylated HIV-1 Env structure reveals new mode for antibody recognition of the CD4-binding site.
    Gristick HB; von Boehmer L; West AP; Schamber M; Gazumyan A; Golijanin J; Seaman MS; Fätkenheuer G; Klein F; Nussenzweig MC; Bjorkman PJ
    Nat Struct Mol Biol; 2016 Oct; 23(10):906-915. PubMed ID: 27617431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complete epitopes for vaccine design derived from a crystal structure of the broadly neutralizing antibodies PGT128 and 8ANC195 in complex with an HIV-1 Env trimer.
    Kong L; Torrents de la Peña A; Deller MC; Garces F; Sliepen K; Hua Y; Stanfield RL; Sanders RW; Wilson IA
    Acta Crystallogr D Biol Crystallogr; 2015 Oct; 71(Pt 10):2099-108. PubMed ID: 26457433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chinks in the armor of the HIV-1 Envelope glycan shield: Implications for immune escape from anti-glycan broadly neutralizing antibodies.
    Moyo T; Ferreira RC; Davids R; Sonday Z; Moore PL; Travers SA; Wood NT; Dorfman JR
    Virology; 2017 Jan; 501():12-24. PubMed ID: 27846415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conserved Role of an N-Linked Glycan on the Surface Antigen of Human Immunodeficiency Virus Type 1 Modulating Virus Sensitivity to Broadly Neutralizing Antibodies against the Receptor and Coreceptor Binding Sites.
    Townsley S; Li Y; Kozyrev Y; Cleveland B; Hu SL
    J Virol; 2016 Jan; 90(2):829-41. PubMed ID: 26512079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasticity and Epitope Exposure of the HIV-1 Envelope Trimer.
    Powell RLR; Totrov M; Itri V; Liu X; Fox A; Zolla-Pazner S
    J Virol; 2017 Sep; 91(17):. PubMed ID: 28615206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple Antibody Lineages in One Donor Target the Glycan-V3 Supersite of the HIV-1 Envelope Glycoprotein and Display a Preference for Quaternary Binding.
    Longo NS; Sutton MS; Shiakolas AR; Guenaga J; Jarosinski MC; Georgiev IS; McKee K; Bailer RT; Louder MK; O'Dell S; Connors M; Wyatt RT; Mascola JR; Doria-Rose NA
    J Virol; 2016 Dec; 90(23):10574-10586. PubMed ID: 27654288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of Novel Structural Determinants in MW965 Env That Regulate the Neutralization Phenotype and Conformational Masking Potential of Primary HIV-1 Isolates.
    Qualls ZM; Choudhary A; Honnen W; Prattipati R; Robinson JE; Pinter A
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody responses to the HIV-1 envelope high mannose patch.
    Daniels CN; Saunders KO
    Adv Immunol; 2019; 143():11-73. PubMed ID: 31607367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conformational Heterogeneity of the HIV Envelope Glycan Shield.
    Yang M; Huang J; Simon R; Wang LX; MacKerell AD
    Sci Rep; 2017 Jun; 7(1):4435. PubMed ID: 28667249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 Glycan Density Drives the Persistence of the Mannose Patch within an Infected Individual.
    Coss KP; Vasiljevic S; Pritchard LK; Krumm SA; Glaze M; Madzorera S; Moore PL; Crispin M; Doores KJ
    J Virol; 2016 Dec; 90(24):11132-11144. PubMed ID: 27707925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of an N-linked glycan in the V1-loop of HIV-1 gp120 influencing neutralization by anti-V3 antibodies and soluble CD4.
    Gram GJ; Hemming A; Bolmstedt A; Jansson B; Olofsson S; Akerblom L; Nielsen JO; Hansen JE
    Arch Virol; 1994; 139(3-4):253-61. PubMed ID: 7832633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Roles of glycans in interactions between gp120 and HIV broadly neutralizing antibodies.
    Qi Y; Jo S; Im W
    Glycobiology; 2016 Mar; 26(3):251-60. PubMed ID: 26537503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycoengineering HIV-1 Env creates 'supercharged' and 'hybrid' glycans to increase neutralizing antibody potency, breadth and saturation.
    Crooks ET; Grimley SL; Cully M; Osawa K; Dekkers G; Saunders K; Rämisch S; Menis S; Schief WR; Doria-Rose N; Haynes B; Murrell B; Cale EM; Pegu A; Mascola JR; Vidarsson G; Binley JM
    PLoS Pathog; 2018 May; 14(5):e1007024. PubMed ID: 29718999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased Epitope Complexity Correlated with Antibody Affinity Maturation and a Novel Binding Mode Revealed by Structures of Rabbit Antibodies against the Third Variable Loop (V3) of HIV-1 gp120.
    Pan R; Qin Y; Banasik M; Lees W; Shepherd AJ; Cho MW; Kong XP
    J Virol; 2018 Apr; 92(7):. PubMed ID: 29343576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isolation and Structure of an Antibody that Fully Neutralizes Isolate SIVmac239 Reveals Functional Similarity of SIV and HIV Glycan Shields.
    Gorman J; Mason RD; Nettey L; Cavett N; Chuang GY; Peng D; Tsybovsky Y; Verardi R; Nguyen R; Ambrozak D; Biris K; LaBranche CC; Ramesh A; Schramm CA; Zhou J; Bailer RT; Kepler TB; Montefiori DC; Shapiro L; Douek DC; Mascola JR; Roederer M; Kwong PD
    Immunity; 2019 Oct; 51(4):724-734.e4. PubMed ID: 31586542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promiscuous glycan site recognition by antibodies to the high-mannose patch of gp120 broadens neutralization of HIV.
    Sok D; Doores KJ; Briney B; Le KM; Saye-Francisco KL; Ramos A; Kulp DW; Julien JP; Menis S; Wickramasinghe L; Seaman MS; Schief WR; Wilson IA; Poignard P; Burton DR
    Sci Transl Med; 2014 May; 6(236):236ra63. PubMed ID: 24828077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
    Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
    J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition.
    Koch M; Pancera M; Kwong PD; Kolchinsky P; Grundner C; Wang L; Hendrickson WA; Sodroski J; Wyatt R
    Virology; 2003 Sep; 313(2):387-400. PubMed ID: 12954207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.